SonoCloud

Low Intensity Contact Ultrasound Implant 

For Improved Brain Therapy

The treatment of brain tumors using chemotherapy is currently not very effective. One of the major causes is the low penetration of chemotherapeutic agents into the brain due to the blood-brain barrier (BBB).

Many articles in the scientific literature have demonstrated the the blood-brain barrier can be opened using ultrasound in combination with systemic injection of an ultrasound contrast agent. This opening allows for an increased concentration of chemotherapeutic agents in brain tissue. Until now, all of the research in the field has used focused external ultrasound (HIFU) and is limited to small areas in the brain.

Primary brain tumors are often a diffuse disease. The objective of CarThera® is to open a larger zone of the BBB to allow for an optimal penetration of chemotherapy drugs in the brain. In addition, as chemotherapy sessions are performed repeatedly, our ultrasound system is compatible with repeated opening of the BBB in an outpatient setting.

The histological diagnosis or surgical resection of brain tumors requires an opening of the skull. This opening is normally followed by a closing of the skull opening. The idea for the SonoCloud® was to use this opening in the skull to implant an ultrasound device.

 

plug3

“Our primary innovation was to work on a device that emitted unfocused ultrasound from within the skull to avoid distortion of the ultrasound waves and to simplify the technique for repeated treatments. Thus was born the SonoCloud® program” as explained by Pr. Alexandre Carpentier.

 

 

  • unnamed-2
    unnamed-3

     
  • News CarThera

    13.12.2018
    CarThera closes €9M ($10.3M) Series B funding round

    €9M ($10.3M) was raised with three institutional investors, Panakès Partners, Sham Innovation Santé (advised by Turenne Capital) and Supernova Invest via its fund Supernova 2, as well as Group Arnault and historical investors. The proceeds will be used to further advance the SonoCloud technology and develop the clinical pipeline of the company. A multi-center study has already been launched in France and in the US to evaluate the SonoCloud-9 device, a new generation of implant with nine ultrasound emitters, in patients with recurrent glioblastoma. The company also has an on-going clinical study with the SonoCloud-1 device in patients with Alzheimer’s disease and one planned for patients with brain metastases.

    09.06.2018
    ASCO 2018: CarThera presents promising preliminary efficacy data for treating recurrent glioblastoma

    Preliminary data from the first clinical trial of the company’s intracranial ultrasound implant, SonoCloud®, show a good safety profile and promising trends in overall survival.

    Dr. Ahmed Idbaih, AP-HP principal investigator of the Phase 1/2a clinical trial (NCT02253212) presented a preliminary analysis of the data from 21 glioblastoma patients who received 65 SonoCloud® treatments. Overall Survival was increased from 8.5 to 12.9 months in patients who had SonoCloud®-induced BBB opening.

    18.05.2018
    May 2018 – CarThera will participate to BIO 2018 in Boston

    CarThera will participate to the BIO International Convention in Boston on June 4-7 to meet with global biotech and pharma leaders and showcase its SonoCloud device.

    Should you want to meet us at BIO and hear more about SonoCloud – our ultrasound device, aimed at improving treatment efficiency by temporarily opening the Blood Brain Barrier – contact us at contact@carthera.eu and come to Booth 527 at the France Pavilion.